NeuroQore, Inc.

Breakthrough rapid treatment for major depressive disorder and imminent risk of suicide

Company Details

NeuroQore is comprised of a team of passionate and motivated scientists, engineers, and clinicians dedicated to developing pioneering neuromodulation treatments for various neurobehavioral conditions. We collaborate with world-class universities and research clinics, in order to investigate ways to transform lives. At NeuroQore, we strive to create a world with effective solutions to devastating disorders: major depressive disorder and suicidality.
Major depressive disorder affects approximately 16 million people in the U.S. and 121 million people worldwide, with a global economic burden of $50 billion, annually. Even with the standard of treatment, which includes pharmaceuticals and concurrent cognitive behavioral therapy, 30%-40% will not respond to treatment, thereby classified as “treatment-resistant depression” (TRD). Despite the staggering prevalence of TRD and suicidality, there is limited knowledge of effective interventions within this population.
Currently, an individual’s option for TRD and acute suicidality are repetitive transcranial magnetic stimulation (rTMS) and electroconvulsive therapy (ECT). Ultimately, standard rTMS is inefficient and out-dated, and is not appropriate for acutely suicidal patients. ECT is the gold standard for these conditions, but while ECT can potentially be effective in treating TRD, and thereby suicidal ideation, its delayed onset of effect, which takes two to six weeks, limits its value in treating acutely suicidal patients. In addition, ECT is met with debilitating side effects and a strong element of social stigma for patients. A new treatment for TRD and acute suicidality is a critical priority. It is time that this gap in the health care system is addressed and new innovative approaches be investigated.

  • NeuroQore Demo

Company People

Adrian Chan

Adrian Chan

Mehran Talebinejad

Mehran Talebinejad
CEO & Co-Founder

NeuroQore, Inc. News


You might also be interested in

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.